Dopamine/glutamate interactions in Parkinson's disease
Identifieur interne : 001F60 ( Main/Exploration ); précédent : 001F59; suivant : 001F61Dopamine/glutamate interactions in Parkinson's disease
Auteurs : Klaus W. Lange [Allemagne] ; Johannes Kornhuber [Allemagne] ; Peter Riederer [Allemagne]Source :
- Neuroscience and Biobehavioral Reviews [ 0149-7634 ] ; 1997.
Abstract
In Parkinson's disease, the tonic inhibition by basal ganglia output structures may be exacerbated by the action of the subthalamic nucleus. As expected, the reduction of excitatory impact from this structure has been shown to reduce akinesia in monkeys with experimental parkinsonism. The findings of receptor binding studies supporting an increased neuronal activity of efferents of the subthalamic nucleus in patients with Parkinson's disease, suggest that subthalamic nucleotomy or pallidotomy may be effective lesions in the neurosurgical treatment of Parkinson's disease. Systemic administration of glutamate antagonists has been shown to have anti-akinetic effects in animal models of Parkinson's disease. Other observations in monkeys indicate that excitatory amino acids such as glutamate are involved in the pathophysiological cascade of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced neuronal cell death. The neuroprotective effects of competitive and non-competite NMDA (N-methyl-d-aspartate) receptor antagonists against MPTP toxicity support the hypothesis that NMDA receptor-mediated events are involved in the neurotoxicity of MPTP. Glutamate antagonists may therefore be able to retard the progression and to improve the symptomatology of Parkinson's disease. Several compounds with anti-parkinsonian effects such as amantadine, memantine, budipine and orphenadrine have been shown to be non-competitive NMDA receptor antagonists and are candidates for clinical trials on the neuroprotective efficacy of NMDA receptor antagonism. Furthermore, glutamate antagonists are useful in the treatment of the akinetic parkinsonian crisis, a severe form of clinical deterioration in patients with Parkinson's disease.
Url:
DOI: 10.1016/S0149-7634(96)00043-7
Affiliations:
- Allemagne
- Bade-Wurtemberg, Bavière, District de Basse-Franconie, District de Fribourg-en-Brisgau
- Fribourg-en-Brisgau, Wurtzbourg
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Dopamine/glutamate interactions in Parkinson's disease</title><author><name sortKey="Lange, Klaus W" sort="Lange, Klaus W" uniqKey="Lange K" first="Klaus W." last="Lange">Klaus W. Lange</name></author><author><name sortKey="Kornhuber, Johannes" sort="Kornhuber, Johannes" uniqKey="Kornhuber J" first="Johannes" last="Kornhuber">Johannes Kornhuber</name></author><author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E01A382075F0C2EBBEA1D21DFE22DF3AB01EF8DC</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0149-7634(96)00043-7</idno><idno type="url">https://api.istex.fr/document/E01A382075F0C2EBBEA1D21DFE22DF3AB01EF8DC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001429</idno><idno type="wicri:Area/Main/Curation">001213</idno><idno type="wicri:Area/Main/Exploration">001F60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Dopamine/glutamate interactions in Parkinson's disease</title><author><name sortKey="Lange, Klaus W" sort="Lange, Klaus W" uniqKey="Lange K" first="Klaus W." last="Lange">Klaus W. Lange</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neuropsychology and Behavioural Neurobiology, University of Freiburg, 79085 Freiburg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Fribourg-en-Brisgau</settlement></placeName></affiliation></author><author><name sortKey="Kornhuber, Johannes" sort="Kornhuber, Johannes" uniqKey="Kornhuber J" first="Johannes" last="Kornhuber">Johannes Kornhuber</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Clinical Neurochemistry, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Clinical Neurochemistry, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Neuroscience and Biobehavioral Reviews</title><title level="j" type="abbrev">NBR</title><idno type="ISSN">0149-7634</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="393">393</biblScope><biblScope unit="page" to="400">400</biblScope></imprint><idno type="ISSN">0149-7634</idno></series><idno type="istex">E01A382075F0C2EBBEA1D21DFE22DF3AB01EF8DC</idno><idno type="DOI">10.1016/S0149-7634(96)00043-7</idno><idno type="PII">S0149-7634(96)00043-7</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0149-7634</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In Parkinson's disease, the tonic inhibition by basal ganglia output structures may be exacerbated by the action of the subthalamic nucleus. As expected, the reduction of excitatory impact from this structure has been shown to reduce akinesia in monkeys with experimental parkinsonism. The findings of receptor binding studies supporting an increased neuronal activity of efferents of the subthalamic nucleus in patients with Parkinson's disease, suggest that subthalamic nucleotomy or pallidotomy may be effective lesions in the neurosurgical treatment of Parkinson's disease. Systemic administration of glutamate antagonists has been shown to have anti-akinetic effects in animal models of Parkinson's disease. Other observations in monkeys indicate that excitatory amino acids such as glutamate are involved in the pathophysiological cascade of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced neuronal cell death. The neuroprotective effects of competitive and non-competite NMDA (N-methyl-d-aspartate) receptor antagonists against MPTP toxicity support the hypothesis that NMDA receptor-mediated events are involved in the neurotoxicity of MPTP. Glutamate antagonists may therefore be able to retard the progression and to improve the symptomatology of Parkinson's disease. Several compounds with anti-parkinsonian effects such as amantadine, memantine, budipine and orphenadrine have been shown to be non-competitive NMDA receptor antagonists and are candidates for clinical trials on the neuroprotective efficacy of NMDA receptor antagonism. Furthermore, glutamate antagonists are useful in the treatment of the akinetic parkinsonian crisis, a severe form of clinical deterioration in patients with Parkinson's disease.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bade-Wurtemberg</li><li>Bavière</li><li>District de Basse-Franconie</li><li>District de Fribourg-en-Brisgau</li></region><settlement><li>Fribourg-en-Brisgau</li><li>Wurtzbourg</li></settlement></list><tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Lange, Klaus W" sort="Lange, Klaus W" uniqKey="Lange K" first="Klaus W." last="Lange">Klaus W. Lange</name></region><name sortKey="Kornhuber, Johannes" sort="Kornhuber, Johannes" uniqKey="Kornhuber J" first="Johannes" last="Kornhuber">Johannes Kornhuber</name><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E01A382075F0C2EBBEA1D21DFE22DF3AB01EF8DC
|texte= Dopamine/glutamate interactions in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |